Glycopeptide Antibiotics: How Vancomycin and Its Relatives Kill Gram-Positive Bacteria

Glycopeptides are one of the most important classes of antibiotics for serious Gram-positive infections, including MRSA. Their name describes their structure: a complex peptide scaffold decorated with sugars (glyco-). Understanding how they work explains a great deal about modern infection treatment — from why oral and IV vancomycin are used so differently to why vancomycin-resistant enterococci are such a concern.

The target: D-Ala-D-Ala

Bacteria build their cell wall from a mesh called peptidoglycan. The building blocks are assembled with a short peptide tail that ends in two D-alanine residues (D-alanyl-D-alanine, or D-Ala-D-Ala). Enzymes then cross-link these tails to give the wall its strength.

Glycopeptides work by binding the D-Ala-D-Ala terminus itself. By capping this end, they physically block the cross-linking enzymes from reaching their substrate. The wall can't be completed, and the bacterium — unable to withstand its own internal pressure — dies. It's a beautifully specific mechanism: the drug binds a substrate, not an enzyme.

Why only Gram-positive bacteria

The D-Ala-D-Ala target sits on the outside of the cell wall, so glycopeptides don't need to enter the cell. But these are large, bulky molecules, and Gram-negative bacteria have an additional outer membrane that the drug can't cross to reach the wall beneath. This is why the entire glycopeptide class — vancomycin included — is active only against Gram-positive organisms. Resistant Gram-negatives need a completely different approach, such as the polymyxins.

The members of the class

• Vancomycin — the decades-old cornerstone for MRSA and other serious Gram-positive infections. Dosed by weight and kidney function with drug-level monitoring. Oral vancomycin (barely absorbed) is a separate, gut-directed treatment for Clostridioides difficile colitis.
• Teicoplanin — a related glycopeptide used across Europe and many regions, with a long half-life allowing once-daily dosing. Not marketed in the US.
• Lipoglycopeptides — semisynthetic derivatives with an added lipophilic tail that increases potency and dramatically extends half-life: dalbavancin and oritavancin can treat a skin infection in a single infusion, and telavancin adds a membrane-disrupting mechanism.

Resistance: when D-Ala-D-Ala becomes D-Ala-D-Lac

The most important resistance mechanism is elegant and worrying. Some bacteria — most notably vancomycin-resistant enterococci (VRE) — remodel their cell-wall precursors to end in D-alanyl-D-lactate (D-Ala-D-Lac) instead of D-Ala-D-Ala. This single change removes a hydrogen bond that vancomycin relies on, weakening binding roughly a thousandfold. The wall still gets built, but the antibiotic can no longer cap it.

Because glycopeptides are such key drugs, this resistance is a serious problem, and it drives antibiotic stewardship — reserving these antibiotics, dosing them correctly, and matching them to susceptibility testing so they keep working.

The "red man" / flushing reaction

A frequently misunderstood point: rapid IV infusion of vancomycin can cause flushing, itching, and a rash (historically "red man syndrome," now the vancomycin flushing reaction). This is not an allergy — it's non-allergic histamine release driven by infusion speed, and it's prevented by slowing the infusion. Distinguishing it from a true allergic reaction matters, because the two are managed very differently.

The takeaway

Glycopeptides — and their newer lipoglycopeptide cousins — are peptide antibiotics that kill Gram-positive bacteria by capping the D-Ala-D-Ala building block of the cell wall. Their specificity, their Gram-positive-only spectrum, their resistance mechanism (D-Ala-D-Lac), and their careful dosing all follow logically from that one mechanism. They remain essential tools against MRSA and other resistant Gram-positive infections — which is exactly why using them wisely matters so much.

This article is educational and does not constitute medical advice. Antibiotics are prescription medicines used under professional guidance.